Barinthus Biotherapeutics plc - American Depositary Shares (BRNS)
BRNS moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How BRNS actually reacts to news — the realized, point-in-time move the market made, measured across 92 labeled events over the last three years with zero look-ahead.
BRNS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 52 |
| 30-min | 0.00% | 46% | 59 |
| 60-min | +1.02% | 55% | 67 |
| to close | 0.00% | 48% | 73 |
| Middle 50% of BRNS reactions | -2.48% to +2.44% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 92 |
Half of all Barinthus Biotherapeutics plc - American Depositary Shares news events land between -2.48% and +2.44% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BRNS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BRNS's baseline. Nothing else.
Recent BRNS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight | Press release | PR Newswire | — | — | |
| Form 15-12G Barinthus Biotherapeutic | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT Barinthus Biotherapeutic | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 25 Barinthus Biotherapeutic | SEC filing · Form 25 | SEC EDGAR | — | — | |
| Form 8-K Barinthus Biotherapeutic For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Barinthus Biotherapeutic | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Barinthus Biotherapeutic | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Barinthus Biotherapeutic For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | +0.40% | -1.98% | |
| Form 8-K Barinthus Biotherapeutic For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | +1.52% | |
| Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics | Press release | GlobeNewswire | +1.52% | +1.52% | |
| Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments | Press release | GlobeNewswire | +0.00% | -0.88% | |
| Form 10-Q Barinthus Biotherapeutic For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.88% | |
| Form 8-K Barinthus Biotherapeutic For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.88% | |
| Form 8-K Barinthus Biotherapeutic For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.69% | |
| Form ARS Barinthus Biotherapeutic For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | +4.91% | |
| Form DEF 14A Barinthus Biotherapeutic For: Jul 02 | SEC filing · Form DEF | SEC EDGAR | — | +4.91% | |
| Form 8-K Barinthus Biotherapeutic For: May 20 | SEC filing · Form 8-K | SEC EDGAR | — | -0.89% | |
| Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments | Press release | GlobeNewswire | +4.38% | +6.56% | |
| Form 10-Q Barinthus Biotherapeutic For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +4.38% | +6.56% | |
| Form 8-K Barinthus Biotherapeutic For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +4.38% | +6.56% | |
| Form DEFM14A Barinthus Biotherapeutic | SEC filing · Form DEFM14A | SEC EDGAR | +4.38% | +6.56% | |
| Form 8-K Barinthus Biotherapeutic For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | — | -3.97% | |
| Form 8-K Barinthus Biotherapeutic For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.02% | |
| Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments | Press release | GlobeNewswire | +0.00% | +6.61% | |
| Form 10-K Barinthus Biotherapeutic For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +6.61% | |
| Form 8-K Barinthus Biotherapeutic For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.61% | |
| Form 8-K Barinthus Biotherapeutic For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.65% | |
| Form 8-K Barinthus Biotherapeutic For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | -1.01% | +1.97% | |
| Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease | Press release | GlobeNewswire | -6.44% | -9.74% | |
| Form 8-K Barinthus Biotherapeutic For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | -6.44% | -9.74% | |
| Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments | Press release | GlobeNewswire | -2.08% | -10.83% | |
| Form 10-Q Barinthus Biotherapeutic For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.08% | -10.83% | |
| Form 8-K Barinthus Biotherapeutic For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | -10.83% | |
| ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics | Press release | PR Newswire | +0.74% | -1.11% | |
| Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases | Press release | GlobeNewswire | -2.11% | -11.97% | |
| BRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to Shareholders | Press release | Business Wire | -0.83% | +15.74% | |
| Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments | Press release | GlobeNewswire | +0.00% | +13.28% | |
| Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025 | Press release | ACCESS Newswire | — | -0.96% | |
| Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments | Press release | GlobeNewswire | — | +0.13% | |
| Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments | Press release | GlobeNewswire | +0.00% | +3.06% | |
| Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 | Press release | ACCESS Newswire | +6.77% | +6.24% | |
| Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight | Press release | PR Newswire | +6.77% | +6.24% | |
| Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update | Press release | GlobeNewswire | +0.00% | -9.65% | |
| Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer | Press release | GlobeNewswire | +6.12% | -1.45% | |
| Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B | Press release | GlobeNewswire | +0.36% | -27.88% | |
| Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion | Press release | GlobeNewswire | +0.36% | -27.88% | |
| Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results | Press release | GlobeNewswire | — | +0.11% | |
| Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer | Press release | GlobeNewswire | +0.00% | -1.67% | |
| Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease | Press release | GlobeNewswire | — | -0.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BRNS section they belong to.
Where else BRNS is measured.
BRNS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Barinthus Biotherapeutics plc - American Depositary Shares's median reaction calculated?
Every labeled BRNS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 92 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of BRNS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BRNS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.